| Literature DB >> 35118454 |
Dimitrios G Chatzis1, Konstantinos Kolokathis2, Kalliopi Magounaki1, Stefanos Chatzidakis1, Konstantinos Avramidis2, Marianna Leopoulou3, Theodoros P Angelopoulos4, John Doupis2,4.
Abstract
Type 2 diabetes mellitus (T2DM) is a chronic disease with a constantly increasing prevalence worldwide. It is well established that T2DM affects both the macro- and microvasculature, and its presence is associated with a high risk of acute and chronic cardiovascular events. Traditionally, the management of T2DM has been mainly focused on the optimization of blood glucose levels with the use of antidiabetic medications. During recent years, however, an impressive accumulation of evidence has arisen from studies designed to explore the plausible effects of new antidiabetic drugs on cardiovascular outcomes in patients with diabetes. This review article aims to emphasize the findings of these studies and to highlight the substantial role of the newer classes of antidiabetic drugs in treating T2DM in a holistic, cardiorenal-metabolic approach, thus shifting the paradigm from the traditional, simplistic, glucose-lowering approach. © Touch Medical Media 2021.Entities:
Keywords: Type 2 diabetes mellitus (T2DM); cardiorenal-metabolic; glucose-lowering; treatment
Year: 2021 PMID: 35118454 PMCID: PMC8676106 DOI: 10.17925/EE.2021.17.2.92
Source DB: PubMed Journal: touchREV Endocrinol ISSN: 2752-5457